NR 565 Advanced Pharmacology
2026 NR 565 Advanced Pharmacology Final
Exam Expert solved Questions and Answers
with Rationales
🔬 Pharmacokinetics & Pharmacodynamics (Q1–Q8)
1. A drug with a long half-life will:
A. Reach steady state faster
B. Require more frequent dosing
C. Take longer to reach steady state
D. Have no accumulation
Answer: C
Rationale: Steady state is reached after ~4–5 half-lives; longer half-life delays this.
2. First-pass metabolism occurs in the:
A. Kidneys
B. Liver
C. Lungs
D. Skin
Answer: B
Rationale: Oral drugs are metabolized in the liver before systemic circulation.
3. A competitive antagonist:
A. Permanently binds receptor
B. Can be overcome with increased agonist
C. Increases efficacy
D. Has no receptor affinity
Answer: B
Rationale: Competes at receptor site; effect can be overcome by higher agonist dose.
4. Narrow therapeutic index drugs require:
A. No monitoring
, NR 565 Advanced Pharmacology
B. Drug level monitoring
C. Once-year dosing
D. No dose adjustments
Answer: B
Rationale: Small margin between therapeutic and toxic levels (e.g., digoxin, lithium).
5. CYP450 enzyme induction results in:
A. Increased drug levels
B. Decreased metabolism
C. Decreased drug levels
D. Toxicity always
Answer: C
Rationale: Induction increases metabolism → lowers drug concentration.
6. Protein-bound drugs:
A. Are always inactive
B. Increase free drug when displaced
C. Cannot interact
D. Are excreted unchanged only
Answer: B
Rationale: Displacement increases active free drug → toxicity risk.
7. Bioavailability refers to:
A. Protein binding
B. Fraction reaching circulation
C. Liver enzyme activity
D. Drug potency
Answer: B
8. Steady state is typically reached after:
A. 1–2 half-lives
B. 2–3 half-lives
C. 4–5 half-lives
D. 10 half-lives
2026 NR 565 Advanced Pharmacology Final
Exam Expert solved Questions and Answers
with Rationales
🔬 Pharmacokinetics & Pharmacodynamics (Q1–Q8)
1. A drug with a long half-life will:
A. Reach steady state faster
B. Require more frequent dosing
C. Take longer to reach steady state
D. Have no accumulation
Answer: C
Rationale: Steady state is reached after ~4–5 half-lives; longer half-life delays this.
2. First-pass metabolism occurs in the:
A. Kidneys
B. Liver
C. Lungs
D. Skin
Answer: B
Rationale: Oral drugs are metabolized in the liver before systemic circulation.
3. A competitive antagonist:
A. Permanently binds receptor
B. Can be overcome with increased agonist
C. Increases efficacy
D. Has no receptor affinity
Answer: B
Rationale: Competes at receptor site; effect can be overcome by higher agonist dose.
4. Narrow therapeutic index drugs require:
A. No monitoring
, NR 565 Advanced Pharmacology
B. Drug level monitoring
C. Once-year dosing
D. No dose adjustments
Answer: B
Rationale: Small margin between therapeutic and toxic levels (e.g., digoxin, lithium).
5. CYP450 enzyme induction results in:
A. Increased drug levels
B. Decreased metabolism
C. Decreased drug levels
D. Toxicity always
Answer: C
Rationale: Induction increases metabolism → lowers drug concentration.
6. Protein-bound drugs:
A. Are always inactive
B. Increase free drug when displaced
C. Cannot interact
D. Are excreted unchanged only
Answer: B
Rationale: Displacement increases active free drug → toxicity risk.
7. Bioavailability refers to:
A. Protein binding
B. Fraction reaching circulation
C. Liver enzyme activity
D. Drug potency
Answer: B
8. Steady state is typically reached after:
A. 1–2 half-lives
B. 2–3 half-lives
C. 4–5 half-lives
D. 10 half-lives
